Chronic lymphocytic leukemia (CLL) is diagnosed by the presence of a specific
immunophenotype of clonal B cells in the peripheral blood. Prognostic models such as the …

Umbralisib (UKONIQ™) is an oral, first-in-class dual phosphatidylinositol 3-kinase delta
(PI3Kδ) and casein kinase 1 epsilon (CK1ε) inhibitor being developed by TG Therapeutics …

Simple Summary Despite being a slow-proliferating disease, chronic lymphocytic leukemia
(CLL) is an incurable and frequently reoccurring adult leukemia. Although large-scale …

Introduction Venetoclax, an oral, BCL-2 inhibitor, is approved by the FDA for treatment of
CLL in all lines of therapy. Data from landmark studies, including the CLL14 and MURANO …

A remarkable evolution in the approach to the treatment of chronic lymphocytic leukemia
(CLL) has occurred over the past decade. Cytotoxic chemoimmunotherapy, established as …

Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized
the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed …

The development of inhibitors of Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-
2) has dramatically improved outcomes in both treatment-naive and previously treated …